Literature DB >> 14579248

DNMT cooperativity--the developing links between methylation, chromatin structure and cancer.

Assam El-Osta1.   

Abstract

Controversy has reigned for some time over the biological connection between DNA methylation and cancer. For this reason, the methylation mechanism responsible for increased cancer risk has received greater attention in recent years. Tumor suppressor genes are often hypermethylated resulting in gene silencing. Although some have questioned this interpretation of the link between methylation and cancer, it appears that both hypermethylation and hypomethylation events can create epigenetic changes that can contribute to cancer development. Recent studies have shown that the methyltransferases DNMT1 and DNMT3b cooperatively maintain DNA methylation and gene silencing in human cancer cells. Disruption of the human DNMT3b only slightly reduces the overall global DNA methylation; however, demethylation was markedly potentiated when both DNMT1 and DNMT3b were simultaneously deleted. The results to these experiments provide compelling evidence towards a role for DNA methylation in cancer. This review discusses the current understanding of cancer-epigenetic information and highlights recent studies that connect the methylation machinery and chromatin remodelling with cancer susceptibility. Copyright 2003 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14579248     DOI: 10.1002/bies.10345

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  14 in total

Review 1.  DNA hypomethylation in the origin and pathogenesis of human diseases.

Authors:  Igor P Pogribny; Frederick A Beland
Journal:  Cell Mol Life Sci       Date:  2009-03-27       Impact factor: 9.261

Review 2.  Chromatin, cancer and drug therapies.

Authors:  Connie C Cortez; Peter A Jones
Journal:  Mutat Res       Date:  2008-07-22       Impact factor: 2.433

Review 3.  Epigenetic phenomena linked to diabetic complications.

Authors:  Luciano Pirola; Aneta Balcerczyk; Jun Okabe; Assam El-Osta
Journal:  Nat Rev Endocrinol       Date:  2010-11-02       Impact factor: 43.330

Review 4.  Folate and epigenetic mechanisms in neural tube development and defects.

Authors:  Sivan Vadakkadath Meethal; Kirk J Hogan; Chandra S Mayanil; Bermans J Iskandar
Journal:  Childs Nerv Syst       Date:  2013-09-07       Impact factor: 1.475

5.  MicroRNA-148a can regulate runt-related transcription factor 3 gene expression via modulation of DNA methyltransferase 1 in gastric cancer.

Authors:  Junbo Zuo; Jiazeng Xia; Feng Ju; Jiang Yan; Akao Zhu; Shimao Jin; Ting Shan; Hong Zhou
Journal:  Mol Cells       Date:  2013-03-29       Impact factor: 5.034

6.  DNA methyltransferase 1 regulates reelin mRNA expression in mouse primary cortical cultures.

Authors:  Jai Sung Noh; Rajiv P Sharma; Marin Veldic; Alain A Salvacion; Xiaomei Jia; Ying Chen; Erminio Costa; Alessandro Guidotti; Dennis R Grayson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-25       Impact factor: 11.205

7.  PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines.

Authors:  Norazizah Shafee; Stefan Kaluz; Ning Ru; Eric J Stanbridge
Journal:  Cancer Lett       Date:  2009-04-01       Impact factor: 8.679

8.  Dnmt1 deficiency promotes CAG repeat expansion in the mouse germline.

Authors:  Vincent Dion; Yunfu Lin; Leroy Hubert; Robert A Waterland; John H Wilson
Journal:  Hum Mol Genet       Date:  2008-02-05       Impact factor: 6.150

Review 9.  Promoter methylation in prostate cancer and its application for the early detection of prostate cancer using serum and urine samples.

Authors:  Hafiz Ahmed
Journal:  Biomark Cancer       Date:  2010-02-18

10.  Chemically induced DNA hypomethylation in breast carcinoma cells detected by the amplification of intermethylated sites.

Authors:  Bekim Sadikovic; Thomas R Haines; Darci T Butcher; David I Rodenhiser
Journal:  Breast Cancer Res       Date:  2004-04-30       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.